SHILPAMED

Shilpa Medicare ; Co Signs Strategic Biotech Partnership with NXI Therapeutics • 🤝 Strategic Collaboration: Shilpa Medicare partners with NXI Therapeutics AG for long-term development and commercial manufacturing support. • 🧬 CDMO Growth Boost: Agreement covers CMC development, process scale-up, GMP clinical supply and commercial manufacturing — strengthening Shilpa’s CDMO platform. • 🌍 Global Mandate: Marks the third major international contract for Shilpa in recent months, improving global biotech visibility. • 📈 Long-Term Revenue Visibility: Includes milestone-linked expansion potential and possibility of multi-year commercial supply agreements. • 🚀 High-Value Segment Entry: Partnership focuses on fast-growing autoimmune & immuno-modulation therapies with strong long-term demand potential. 🟢 Impact: Positive Strengthens international CDMO pipeline, enhances long-term revenue visibility, and supports Shilpa’s transition toward high-value biologics and specialty therapeutics